论文部分内容阅读
为探讨纤溶酶原激活抑制剂 1 (PAI 1 )基因调节区 -675bp位点 4G/5G多态性与 2型糖尿病、2型糖尿病合并冠心病 (CAD)的关系 ,采用特异性引物聚合酶链反应 (PCR)方法 ,测定 4G/5G基因型 ,并检测PAI 1抗原水平 ,共观察了 1 2 1例单纯 2型糖尿病 (typeⅡdiabetes)患者、87例 2型糖尿病合并CAD患者和 1 0 0例对照者。结果 :合并CAD组的 4G/4G基因型携带者明显高于对照组 ( 4 9.4%比 3 7.0 % ,P <0 .0 5 ) ,CAD组中PAI 1与三酰甘油 (TG)呈正相关 ,并与 4G/5G多态性有关 ,表现为 4G/4G基因型携带者的PAI 1质量浓度明显高于 5G/5G基因型携带者〔( 3 9.82× 1 0 - 3± 3 .1 1× 1 0 - 3)ng/L比 ( 3 8.0 4× 1 0 - 3± 2 .73× 1 0 - 3)ng/L ,P <0 .0 5〕。提示 :PAI 1基因 4G/5G多态性与TG的联合作用与PAI 1抗原水平相关 ,并与 2型糖尿病合并CAD的发病过程有关。
To explore the relationship between the polymorphism of -675bp 4G / 5G polymorphism of plasminogen activator inhibitor 1 (PAI 1) gene and type 2 diabetes mellitus and type 2 diabetes with coronary heart disease (CAD), a specific primer polymerase PCR method was used to determine the genotype of 4G / 5G and to detect the PAI 1 antigen level. A total of 121 patients with type Ⅱ diabetes, 87 patients with type 2 diabetes mellitus complicated with CAD and 100 patients with CAD Controllers. Results: 4G / 4G genotype carriers in the combined CAD group were significantly higher than those in the control group (4 9.4% vs. 3.07%, P <0.05). There was a positive correlation between PAI 1 and triglyceride (TG) And was associated with 4G / 5G polymorphism. The PAI 1 concentration of 4G / 4G genotype carriers was significantly higher than that of 5G / 5G genotype carriers [(3 9.82 × 10-3 ± 3.11 × 1 0-3) ng / L ratio (3 8.0 4 × 10-3 ± 2.73 × 10-3 ng / L, P <0.05). It is suggested that the combined effect of 4G / 5G polymorphism of PAI 1 gene and TG is related to the level of PAI 1 antigen and is associated with the pathogenesis of type 2 diabetes complicated with CAD.